Discover the world's scientific knowledge

With 160+ million publication pages, 25+ million researchers and 1+ million questions, this is where everyone can access science

You can use AND, OR, NOT, "" and () to specify your search.

PublicationsAuthorsQuestions
First-versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
Article
  • Apr 2023
  • DOI: 10.3390/cancers15082382
  • ISBN: 2072-6694
  • Vineeth Tatineni
    Vineeth Tatineni
  • P.J. O'Shea
    P.J. O'Shea
  • Ahmad Ozair
    Ahmad Ozair
  • Atulya Aman Khosla
    Atulya Aman Khosla
  • Shreya Saxena
    Shreya Saxena
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)
Article
  • Dec 2022
  • DOI: 10.1186/s12885-022-10409-6
  • ISBN: 1471-2407
  • Tomoya Fukui
    Tomoya Fukui
  • Jiichiro Sasaki
    Jiichiro Sasaki
  • Satoshi Igawa
    Satoshi Igawa
  • Akiko Kada
    Akiko Kada
  • Toshiki I. Saito
    Toshiki I. Saito
Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature
Article
  • Aug 2023
  • DOI: 10.1097/MD.0000000000034545
  • ISBN: 0025-7974
  • Qiang Guo
    Qiang Guo
  • Weiqiang Feng
    Weiqiang Feng
  • Sheng Hu
    Sheng Hu
  • Jiayue Ye
    Jiayue Ye
  • Silin Wang
    Silin Wang
Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis
Article
  • Apr 2023
  • DOI: 10.1007/s41669-023-00407-0
  • ISBN: 2509-4254
  • Julie Vanderpoel
    Julie Vanderpoel
  • Bruno Emond
    Bruno Emond
  • Isabelle Ghelerter
    Isabelle Ghelerter
  • Katherine Milbers
    Katherine Milbers
  • Marie-Hélène Lafeuille
    Marie-Hélène Lafeuille
Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
Article
  • Aug 2023
  • DOI: 10.3389/fonc.2023.1182391
  • ISBN: 2234-943X
  • Michael Cekay
    Michael Cekay
  • Philipp Friedrich Arndt
    Philipp Friedrich Arndt
  • Rio Dumitrascu
    Rio Dumitrascu
  • Rajkumar Savai
    Rajkumar Savai
  • Andreas Bräuninger
    Andreas Bräuninger
Efficacy of Osimertinib for EGFR Exon 20 Insertion Mutation-positive Non-small Cell Lung Cancer with Brain Metastases in a Very Elderly Man
Article
  • Feb 2023
  • DOI: 10.2482/haigan.63.33
  • ISBN: 0386-9628
  • Yosuke Kakiuchi
    Yosuke Kakiuchi
  • Toshimi Satoh
    Toshimi Satoh
  • Ryoichi Nakai
    Ryoichi Nakai
+2
Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
Article
  • Jun 2023
  • DOI: 10.3389/fonc.2023.1104098
  • ISBN: 2234-943X
  • Cheng-Yu Chang
    Cheng-Yu Chang
  • Chung-Yu Chen
    Chung-Yu Chen
  • Shih-Chieh Chang
    Shih-Chieh Chang
  • Ching-Yi Chen
    Ching-Yi Chen
  • Yi-Chun Lai
    Yi-Chun Lai
Preview image for Two case reports of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy
Source
Two case reports of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy
Article
  • Jun 2022
  • DOI: 10.21037/atm-22-2436
  • ISBN: 2305-5839
  • Zizheng Song
    Zizheng Song
  • Guanying Ren
    Guanying Ren
  • Ling Hu
    Ling Hu
  • Xiaolei Wang
    Xiaolei Wang
  • Jin Song
    Jin Song
Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
Article
  • Aug 2021
  • DOI: 10.2147/OTT.S227032
  • ISBN: 1178-6930
  • Chung-Shien Lee
    Chung-Shien Lee
  • Matthew Milone
    Matthew Milone
  • Nagashree Seetharamu
    Nagashree Seetharamu
Preview image for Treatment tactics of non-small-cell lung cancer with erlotinib: literature review and description of a clinical case
Source
Treatment tactics of non-small-cell lung cancer with erlotinib: literature review and description of a clinical case
Article
  • Dec 2019
  • DOI: 10.21518/2079-701X-2019-19-38-43
  • ISBN: 2079-701X
  • E. I. Borisova
    E. I. Borisova
  • S. L. Gutorov
    S. L. Gutorov
  • M. E. Abramov
    M. E. Abramov
1
2
3
4
5
10
App Store
Get it on Google Play
Company
About us
News
Careers
Support
Help Center
Business solutions
Advertising
Recruiting
© 2008-2023 ResearchGate GmbH. All rights reserved.
  • Terms
  • Privacy
  • Copyright
  • Imprint
Join for free
Log in